source
- Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectationsBiogen officially began reporting revenue from the $5.6 billion acquisition of Apellis in the second quarter, shaking up analysts’ consensus estimates and leading to a beat.
- BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…